In this study, we set out to search for the genes that affect checkpoint molecule expression and ICB treatment efficiency by examining the gene expression pattern of liver cancer patients who may benefit from ICB treatment and identified the oncogene EPDR1 as a potential candidate gene associated with a positive response to ICB treatment. The gene discussed is EPDR1; the disease is liver cancer.